TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05948371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity interval Training
Description: High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic training
Description: Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling.
Study: NCT05088629

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical Tests
Description: Clinical Tests
Study: NCT05072743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Description: PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
Study: NCT04940702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Vibration
Description: Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction
Description: Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
Study: NCT05499351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult group in immunogenicity and safety study of combined immunization
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elderly group in immunogenicity and safety study of combined immunization
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
Study: NCT04940702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Warm up, aerobic training, stenght training, balance and coordination training and return to calm
Study: NCT05421793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented product of carrot derived rhamnogalacturonan I
Description: Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
Study: NCT04997395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MediCabilis Cannabis sativa 50
Description: Already described
Study: NCT06030349

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation
Study: NCT05499351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult group in safety observation study of combined immunization
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elderly group in safety observation study of combined immunization
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
Study: NCT04877171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine neurology consultation
Description: consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in-person neurology consultation
Description: consultation in-person at Hospital Internacional de Colombia
Study: NCT06456879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extra-coronal restoration type
Description: primary molar crown type

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extra-coronal restoration type
Description: primary molar crown type
Study: NCT06131268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
Study: NCT05510245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: One PF-07081532 20 mg tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: One PF-07081532 20 mg tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: One PF-07081532 20 mg tablet, administered orally
Study: NCT06759623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different drug type for conduction of general anesthesia
Description: Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different drug type for conduction of general anesthesia
Description: Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
Study: NCT05806047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide combined with fulvestrant
Description: chidamide combined with fulvestrant
Study: NCT04634773

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Description: A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose CT
Description: A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1Rho MRI
Description: A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T1Rho MRI
Description: A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.
Study: NCT06373796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echographic scan
Description: Liver ultrasound exam
Study: NCT06358820

Intervention type: DRUG
Group type: OTHER
Intervention: Amino acid peritoneal dialysis solution
Description: Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
Study: NCT05595096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with preservation of spontaneous breathing
Description: non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
Study: NCT06428422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Bl-04
Description: 4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo
Description: 1 g/day maltodextrin for 12 weeks
Study: NCT05915078

Intervention type: COMBINATION_PRODUCT
Intervention: Iontophoresis and tube placement
Description: Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
Study: NCT05259514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
Study: NCT04634773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion Analysis
Description: Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years.
Study: NCT05510245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: One PF-07081532 20 mg tablet, administered orally
Study: NCT06716619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Injection
Description: Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.
Study: NCT05938894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online games with various food images
Description: Participant will play a series of online games with various food images.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online games with images of flowers and songbirds
Description: Participant will play a series of online games with images of flowers and songbirds.
Study: NCT05475106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptides
Description: Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
Study: NCT06196957

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pursed lip breathing
Description: pursed lip breathing

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: pursed lip breathing
Description: pursed lip breathing
Study: NCT06067412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Efficacy in fits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin
Description: Efficacy in fits
Study: NCT04977609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR+MUSIC
Description: A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
Study: NCT06719258

Intervention type: DEVICE
Intervention: MR850
Description: This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.

Intervention type: DEVICE
Intervention: FP950
Description: This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
Study: NCT06717789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device
Description: Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• High Intensity TENS (50-150 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device
Description: Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• Low Intensity TENS (5 Hz)
Study: NCT06717477

Intervention type: PROCEDURE
Intervention: Changes to the care pathway for carpal tunnel syndrome (The Carpal Tunnel Plus Pathway)
Description: Changes to the care pathway for carpal tunnel syndrome. Features of the CTS+ pathway include new referral form, care map for mild, moderate and severe CTS established, point or care ultrasound with steroid injection introduced, and expedited referral to surgeons.
Study: NCT06718725

Intervention type: DIAGNOSTIC_TEST
Intervention: ROSE-AI system
Description: The cytopathological slide images of the patients' ROSE samples will be identified by the ROSE-AI system.
Study: NCT05638828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD14-01 Cell injection
Description: RD14-01 Cell injection
Study: NCT05610735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withaferin A
Description: Ashwagandha in the form of tablets will be administered orally on daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Administered orally on daily basis twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of ASWD and DOXIL
Description: DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
Study: NCT04977609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR
Description: A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
Study: NCT05442736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
Study: NCT06210971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal irinotecan
Description: Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation threapy
Description: 50.4Gy/28 fractions
Study: NCT05403710

Intervention type: DRUG
Intervention: Botulinum toxin
Description: Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Study: NCT06405542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX-CIPN
Description: The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals.
Study: NCT05229614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Therapy
Description: After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy (Pembrolizumab)
Description: Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
Study: NCT05120492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery followed by total knee replacement
Description: The only intervention is the randomization of the priority of the 2 procedures.
Study: NCT06414668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Intervention Group
Description: A eight-weeks school-based cycling program. The school-based cycling intervention consists of 2 Bikeability sessions of 60 min at Physical Education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training. In addition, participants will receive encouragement strategies, one for each week of the intervention, for cycling to and from school during eight weeks.